Liquidia Corporation (LQDA)
Automate Your Wheel Strategy on LQDA
With Tiblio's Option Bot, you can configure your own wheel strategy including LQDA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LQDA
- Rev/Share 0.1661
- Book/Share 0.5837
- PB 22.564
- Debt/Equity 2.9703
- CurrentRatio 2.9281
- ROIC -0.6231
- MktCap 1125830865.0
- FreeCF/Share -1.2609
- PFCF -10.4836
- PE -8.7749
- Debt/Assets 0.6493
- DivYield 0
- ROE -1.7031
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | LQDA | Oppenheimer | Perform | Underperform | -- | $13 | May 19, 2025 |
| Initiation | LQDA | Wells Fargo | -- | Overweight | -- | $20 | Dec. 20, 2024 |
| Initiation | LQDA | Scotiabank | -- | Sector Outperform | -- | -- | Oct. 16, 2024 |
| Upgrade | LQDA | Raymond James | Outperform | Strong Buy | -- | -- | Aug. 19, 2024 |
| Initiation | LQDA | Raymond James | -- | Outperform | -- | $27 | Aug. 16, 2024 |
News
Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
MORRISVILLE, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that Liquidia is scheduled to make its first commercial shipment of YUTREPIA™ (treprostinil) inhalation powder, marking the first time YUTREPIA will be available to be prescribed to patients at specialty pharmacies. This milestone was achieved only five business days following the U.S. Food and Drug Administration (FDA) approval of YUTREPIA on May 23, 2025, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Read More
U.S. FDA Approves Liquidia's YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
Published: May 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
MORRISVILLE, N.C., May 23, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that the U.S. Food and Drug Administration (FDA) has approved YUTREPIA™ (treprostinil) inhalation powder, a prostacyclin analog for adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) to improve exercise ability. YUTREPIA is the first and only prostacyclin dry-powder formulation enabled by Liquidia's proprietary PRINT™ technology, which yields uniform, free-flowing particles designed to enhance deep-lung delivery via an easy-to-use, low-effort device requiring less inspiratory effort.
Read More
Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
MORRISVILLE, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that United Therapeutics Corporation (UTHR) filed a complaint on May 9, 2025, in the U.S. District Court for the Middle District of North Carolina (Case No. 1:25-cv-00368) against Liquidia alleging infringement of U.S. Patent No. 11,357,782 (the ‘782 patent). Additionally, the complaint seeks to enjoin Liquidia from commercializing YUTREPIA™ (treprostinil) inhalation powder if approved by the U.S. Food and Drug Administration (FDA) to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial …
Read More
Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Misses Revenue Estimates
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Negative
Liquidia Technologies, Inc. (LQDA) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.54 per share a year ago.
Read More
Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
MORRISVILLE, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today reported financial results for the first quarter ended March 31, 2025. The company will also host a webcast at 8:30 a.m. ET on May 8, 2025 to discuss its financial results and provide a corporate update.
Read More
Liquidia Technologies (LQDA) Surges 13.2%: Is This an Indication of Further Gains?
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Liquidia Technologies (LQDA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Read More
Liquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
MORRISVILLE, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its first quarter 2025 financial results on Thursday, May 8, 2025.
Read More
Arquitos Capital's Largest Holdings For Q1 2025
Published: April 30, 2025 by: Seeking Alpha
Sentiment: Positive
ENDI Corp's shares rose significantly, driven by a substantial increase in AUM and a value-unlocking transaction, suggesting further upside potential. Finch Therapeutics awaits a post-trial decision that could significantly impact its share value, with a minimum award level already set. Nam Tai Property secured significant financing and sold a non-core property above appraisal value, indicating a potential closing of the gap between market price and fair value.
Read More
Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder
Published: March 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
The U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for YUTREPIA™ (treprostinil) inhalation powder.
Read More
Liquidia Corporation (LQDA) Q4 2024 Earnings Call Transcript
Published: March 19, 2025 by: Seeking Alpha
Sentiment: Neutral
Liquidia Corporation (NASDAQ:LQDA ) Q4 2024 Earnings Conference Call March 19, 2025 8:30 AM ET Company Participants Jason Adair - Chief Business Officer Roger Jeffs - CEO Michael Kaseta - COO and CFO Rajeev Saggar - Chief Medical Officer Scott Moomaw - Chief Commercial Officer Rusty Schundler - General Counsel Conference Call Participants Julian Harrison - BTIG Serge Belanger - Needham Ryan Deschner - Raymond James Greg Harrison - Scotiabank Cory Jubinville - LifeSci Capital Operator Good morning. And welcome everyone to Liquidia Corporation Full Year 2024 Financial Results and Corporate Update Conference Call.
Read More
About Liquidia Corporation (LQDA)
- IPO Date 2018-07-26
- Website https://www.liquidia.com
- Industry Biotechnology
- CEO Dr. Roger A. Jeffs Ph.D.
- Employees 170